将 2020 年 AAD-NPF 系统用非生物制剂治疗银屑病的治疗指南转化为临床实践。

Translating the 2020 AAD-NPF Guidelines of Care for the Management of Psoriasis With Systemic Nonbiologics to Clinical Practice.

机构信息

Ms. Chat is from the Medical College of Georgia at Augusta University. Dr. Uppal is from Albany Medical College, New York. Mr. Kearns is from Loma Linda University School of Medicine, California. Dr. Han is from the Icahn School of Medicine at Mount Sinai, New York, New York. Dr. Wu is from the Dermatology Research and Education Foundation, Irvine, California.

出版信息

Cutis. 2021 Feb;107(2):99-103. doi: 10.12788/cutis.0177.

DOI:10.12788/cutis.0177

PMID:33891841

Abstract

In 2020, the American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) released a set of guidelines for the management of psoriasis in adults with systemic nonbiologic therapies, including acitretin, apremilast, cyclosporine, fumaric acid esters, methotrexate, and tofacitinib. This review addresses dosing, efficacy, toxicity, drug-related interactions, and contraindications alongside evidence-based treatment recommendations for each systemic therapy. Important considerations for treatment such as drug selection, initiation of therapy, drug monitoring, and patient management also are discussed. Physicians are encouraged to use these recommendations to guide treatments based on individual patient needs and disease characteristics.

摘要

2020 年，美国皮肤病学会（AAD）和国家银屑病基金会（NPF）发布了一套成人系统性非生物疗法治疗银屑病的指南，包括阿维 A、阿普米司特、环孢素、富马酸酯、甲氨蝶呤和托法替尼。本综述介绍了每种系统性治疗的剂量、疗效、毒性、药物相互作用和禁忌证，以及基于证据的治疗建议。还讨论了治疗中的重要注意事项，如药物选择、治疗开始、药物监测和患者管理。鼓励医生根据患者的个体需求和疾病特征使用这些建议来指导治疗。